What’s the Evidence for Fluvoxamine in COVID-19?
What’s the Evidence for Fluvoxamine in COVID-19?
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
randomized human studies
Ivermectin (Still) Lacks Scientific Support as a COVID-19 Drug
Catherine Offord | Aug 2, 2021 | 3 min read
A Cochrane review bolsters scientists’ advice that ivermectin should not be used against the disease outside of clinical trials, while a study claiming to have found beneficial effects in patients was withdrawn following allegations of data manipulation.
Indian Study Shows No Survival Benefit of Plasma in COVID-19
Alakananda Dasgupta | Sep 15, 2020 | 5 min read
A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.
Steroid Drugs Are an Effective Treatment for Severe COVID-19: WHO
Catherine Offord | Sep 3, 2020 | 2 min read
A meta-analysis of seven randomized controlled trials concludes that dexamethasone and other corticosteroids reduce 28-day mortality in seriously ill patients.
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Shawna Williams | Aug 14, 2020 | 2 min read
Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.
A New Way to Establish Cause and Effect in Epidemiology?
Rachael Moeller Gorman | Jan 1, 2020 | 7 min read
A technique called Mendelian randomization is overturning the conclusions of observational studies in public health. But researchers question whether the method can overcome its fundamental limitations.
Parkinson’s Researcher Notches 17 Retracted Papers
Aggie Mika | Sep 13, 2017 | 2 min read
Scientific misconduct motivated Yoshihiro Sato’s three additional retractions last month; his institution doesn’t respond.